Translational Research
Rarecells is conducting a clinical study to assess the sensitivity of its new ISET® CTC-DNA workflow in patients with early-stage lung cancer.
The clinical study has already shown, in its first results, superior sensitivity and tumor heterogeneity by analyzing the combinaton of ctDNA and ISET® CTC-DNA.
BioMolCTC Trial -
Agostino Gemelli University Hospital Rome, Italy
In a collaboration with Professor Filippo Lococo from the Agostino Gemelli University and Policlinic Center of Excellence in Rome, Italy, Rarecells is conducting a clinical study on early-stage operable lung cancer patients to comparatively assess the ISET® CTC-DNA and the ctDNA (standard extraction protocol) sensitivity for early cancer and cancer recurrence detection.
Clinical data from the study were presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) in Barcelona. Initial findings demonstrate that combining ISET® CTC-DNA with ctDNA analysis significantly enhances both sensitivity and the detection of tumor heterogeneity.
